Acceliant Revenue and Competitors
Estimated Revenue & Valuation
- Acceliant's estimated annual revenue is currently $362.5k per year.
- Acceliant's estimated revenue per employee is $72,500
Employee Data
- Acceliant has 5 Employees.
- Acceliant grew their employee count by 0% last year.
Acceliant's People
Name | Title | Email/Phone |
---|
Acceliant Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.9M | 29 | 4% | N/A | N/A |
#2 | $43.4M | 272 | 8% | N/A | N/A |
#3 | $14.1M | 97 | 11% | N/A | N/A |
#4 | $1460M | 8291 | 7% | $1.1B | N/A |
#5 | $310M | 1527 | 20% | N/A | N/A |
#6 | $194.1M | 956 | -5% | N/A | N/A |
#7 | $223.9M | 1080 | -33% | $101.6M | N/A |
#8 | $581.3M | 2708 | 9% | $253.1M | N/A |
#9 | $716.2M | 3528 | 2% | N/A | N/A |
#10 | $801.4M | 3948 | 52% | N/A | N/A |
What Is Acceliant?
Acceliant provides real-time, integrated clinical trial solutions for life sciences, CROs and pharma tools and expertise to take intelligent and smarter decisions. Its eClinical Suite allows users to build studies, design electronic case report forms (eCRFs), capture data through multiple sources (EDC), capture data directly from patients (ePRO), and manage other clinical data management functions. A pioneer in the EDC industry, Acceliant has been providing solutions in the clinical trial management space to the industry since 1999. Since then, Acceliant has served customers in the CRO, medical device, pharmaceutical, biotech, and non-profit drug research industries. The Acceliant eClinical Suite has helped facilitate clinical data management in hundreds of trials for global giants as well as emerging healthcare innovators.
keywords:N/AN/A
Total Funding
5
Number of Employees
$362.5k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | 0% | N/A |
#2 | $0.5M | 5 | -55% | N/A |
#3 | $0.4M | 5 | -17% | N/A |
#4 | $0.4M | 5 | 0% | N/A |
#5 | $0.1M | 5 | 0% | $11M |